Actively Recruiting
rTMS as Add on Treatment for Substance Use Disorders
Led by Yale University · Updated on 2025-06-29
80
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This pilot study is designed to test feasibility and superiority of rTMS types and target locations for the optimal rTMS intervention for individuals seeking treatment for Alcohol Use Disorder (AUD) or Opioid Use Disorder (OUD). The critical questions this study seeks to answer are: which rTMS type applied to l-dlPFC in OUD participants will induce the greatest reduction of opioid use post-treatment? Is inhibitory rTMS applied to medial prefrontal cortex (mPFC) more effective than excitatory rTMS applied to l-dlPFC at reducing alcohol use post treatment in AUD participants?
CONDITIONS
Official Title
rTMS as Add on Treatment for Substance Use Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be able to give valid informed consent in English.
- Have an IQ equivalent of 70 or higher on the WRAT.
- Currently receiving treatment for either Alcohol Use Disorder or Opioid Use Disorder.
You will not qualify if you...
- History of neurological disorders increasing seizure risk such as stroke, brain lesions, previous neurosurgery, seizures, fainting episodes of unknown cause, or head trauma with loss of consciousness lasting over 30 minutes or with lasting effects.
- Clinically significant alcohol withdrawal (CIWA-Ar score greater than 5) for AUD participants.
- First-degree family history of epilepsy or multiple sclerosis.
- Presence of cardiac pacemakers, neural stimulators, implantable defibrillators, medication pumps, intracardiac lines, unstable cardiac disease, intracranial implants, or any metal object in the body preventing rTMS.
- Current use of anti- or pro-convulsive medications.
- Use of benzodiazepines within 48 hours before rTMS.
- Lifetime history of schizophrenia, bipolar disorder, or mania.
- History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke, or transient ischemic attack.
- Pregnant or lactating women.
- Any contraindications to TMS.
- Discharge date from treatment center does not allow scheduling all 5 rTMS treatment days.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hartford Healthcare
Hartford, Connecticut, United States, 06102
Actively Recruiting
Research Team
V
Vaughn R Steele, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here